Trial Profile
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Jan 2019
Price :
$35
*
At a glance
- Drugs Vatiquinone (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Expanded access; Therapeutic Use
- Sponsors BioElectronics Corporation; Edison Pharmaceuticals
- 28 Nov 2014 New trial record